- Home
- BEP vs MDGL Comparison
BEP vs MDGL Comparison
Compare BEP & MDGL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | BEP | MDGL |
|---|---|---|
| Founded | 1999 | 2011 |
| Country | Canada | United States |
| Employees | 5870 | N/A |
| Industry | Electric Utilities: Central | Biotechnology: Pharmaceutical Preparations |
| Sector | Utilities | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 10.3B | 11.1B |
| IPO Year | N/A | 2005 |
Fundamental Metrics
Financial Performance| Metric | BEP | MDGL |
|---|---|---|
| Price | $33.89 | $527.95 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 10 | 12 |
| Target Price | $35.70 | ★ $674.45 |
| AVG Volume (30 Days) | ★ 758.8K | 292.8K |
| Earning Date | 05-01-2026 | 05-06-2026 |
| Dividend Yield | ★ 4.71% | N/A |
| EPS Growth | N/A | ★ 41.32 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $180,133,000.00 |
| Revenue This Year | $17.09 | $58.39 |
| Revenue Next Year | N/A | $48.55 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $24.13 | $284.02 |
| 52 Week High | $38.12 | $615.00 |
Technical Indicators
Market Signals| Indicator | BEP | MDGL |
|---|---|---|
| Relative Strength Index (RSI) | 36.71 | 55.75 |
| Support Level | $32.38 | $498.59 |
| Resistance Level | $34.91 | $545.29 |
| Average True Range (ATR) | 1.02 | 21.05 |
| MACD | -0.18 | 3.34 |
| Stochastic Oscillator | 15.55 | 67.33 |
Price Performance
Historical ComparisonAbout BEP Brookfield Renewable Partners L.P.
Brookfield Renewable is a globally diversified, multitechnology owner and operator of clean energy assets. The company's portfolio consists of hydroelectric, wind, solar, and storage facilities in North America, South America, Europe, and Asia and totals over 40 gigawatts of installed capacity. Brookfield Renewable invests in assets directly, as well as with institutional partners, joint venture partners, and through other arrangements. The company offers two separate listings for investors: Brookfield Renewable Partners and Brookfield Renewable Corp.
About MDGL Madrigal Pharmaceuticals Inc.
Madrigal Pharmaceuticals Inc is a biopharmaceutical company focused on delivering novel therapeutics for metabolic dysfunction-associated steatohepatitis (MASH), a serious liver disease with high unmet medical need that can lead to cirrhosis, liver failure, liver cancer, need for liver transplantation and premature mortality. Its medication, Rezdiffra (resmetirom), is a once-daily, oral, liver-directed thyroid hormone receptor beta agonist designed to target key underlying causes of MASH.